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Global Analysis of Myocardial Peptides
Containing Cysteines With Irreversible Sulfinic
and Sulfonic Acid Post-Translational
Modifications*□S
Jana Paulech‡, Kiersten A. Liddy‡§, Kasper Engholm-Keller¶**, Melanie Y. White‡§‡‡,
and Stuart J. Cordwell‡§‡‡§§
Cysteine (Cys) oxidation is a crucial post-translational
modification (PTM) associated with redox signaling and
oxidative stress. As Cys is highly reactive to oxidants it
forms a range of post-translational modifications, some
that are biologically reversible (e.g. disulfides, Cys sul-
fenic acid) and others (Cys sulfinic [Cys-SO2H] and sul-
fonic [Cys-SO3H] acids) that are considered “irreversible.”
We developed an enrichment method to isolate Cys-
SO2H/SO3H-containing peptides from complex tissue ly-
sates that is compatible with tandem mass spectrometry
(MS/MS). The acidity of these post-translational modifica-
tion (pKa Cys-SO3H < 0) creates a unique charge distri-
bution when localized on tryptic peptides at acidic pH that
can be utilized for their purification. The method is based
on electrostatic repulsion of Cys-SO2H/SO3H-containing
peptides from cationic resins (i.e. “negative” selection)
followed by “positive” selection using hydrophilic interac-
tion liquid chromatography. Modification of strong cation
exchange protocols decreased the complexity of initial
flowthrough fractions by allowing for hydrophobic reten-
tion of neutral peptides. Coupling of strong cation ex-
change and hydrophilic interaction liquid chromatography
allowed for increased enrichment of Cys-SO2H/SO3H (up
to 80%) from other modified peptides. We identified 181
Cys-SO2H/SO3H sites from rat myocardial tissue sub-
jected to physiologically relevant concentrations of H2O2
(<100 M) or to ischemia/reperfusion (I/R) injury via Lan-
gendorff perfusion. I/R significantly increased Cys-SO2H/
SO3H-modified peptides from proteins involved in energy
utilization and contractility, as well as those involved in
oxidative damage and repair. Molecular & Cellular Pro-
teomics 14: 10.1074/mcp.M114.044347, 609–620, 2015.
Cysteine (Cys)1 is an integral site for protein post-transla-
tional modification (PTM) in response to physiological and
pathological stimuli. Numerous studies have identified roles
for biologically reversible Cys PTM, including disulfides, S-
nitrosothiols, and sulfenic acids (Cys-SOH), in the regulation
of protein function during redox signaling (reviewed in (1, 2)).
Additionally, Cys can be oxidized in pathologies associated
with oxidative stress (e.g. neurodegeneration, cancer, and
cardiovascular disease (2)). Various redox proteomics meth-
ods exist for enrichment of these reversibly oxidized Cys,
based on reduction to the thiol and then capture by: 1) alky-
lation with a chemical tag (e.g. isotope coded affinity tags)
(3–6); 2) thiol-disulfide exchange (7–10); or 3) heavy metal ion
chelation (11, 12). Oxidative Cys PTMs with predominantly no
known means of enzymatic reduction have also been identi-
fied. These “over” or “irreversibly” oxidized Cys PTM (sulfinic
[Cys-SO2H] and sulfonic [Cys-SO3H] acids) are primarily as-
sociated with oxidative stress. Only one example of reversible
Cys-SO2H modification has been characterized—in peroxire-
doxins (Prx) by the ATP-dependent sulfiredoxin (Srx)(13);
however, Srx is not thought to reduce Cys-SO2H in other
proteins, and no mechanism has yet been found for Cys-
SO3H reduction. At basal levels, 1–2% of Cys exist as
Cys-SO2H/SO3H (14), and the RSO2H modification has func-
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tional significance in some proteins (e.g. DJ-1 is activated in
Alzheimer’s disease by Cys-SO2H at Cys-106) (15).
Cys-SO2H/SO3H are produced via sequential oxidation of
Cys-SOH, which itself is formed because of Cys thiol oxida-
tion by reactive oxygen and nitrogen species (ROS/RNS),
such as hydrogen peroxide (H2O2) or peroxynitrite. This reac-
tion is relatively inefficient and requires three equivalents of
oxidant, as well as the protection of the initial Cys-SOH from
nucleophilic attack. Therefore, Cys forming these PTM, par-
ticularly at biologically relevant concentrations of oxidant, are
likely to be highly reactive or located in a unique microenvi-
ronment that accommodates their production without prior
reduction of the Cys-SOH (e.g. by thiol or amine attack). Such
sites may thus be candidates as redox or regulatory sensors
(reviewed in (16)). Alternatively, over-oxidation to Cys-SO2H/
SO3H during elevated oxidative stress may serve as a marker
of oxidative damage, and target proteins for degradation.
Information on Cys-SO2H/SO3H PTM in complex samples
has thus far been generated only by amino acid analysis
(hydrolyzed lysates) (14) or two-dimensional gel electropho-
resis (2-DE), where these PTM cause an acidic shift (17, 18).
The former provides no information on specific proteins,
whereas the latter relies on the modified population being of
sufficient intensity for observation and/or the availability of
antibodies against a protein-of-interest. A recent study iden-
tified 44 Cys-SO2H/SO3H-modified peptides in nonphysi-
ologically H2O2 oxidized (440 M) cells utilizing long column
ultra-high pressure liquid chromatography (LC) (19). Global
analysis of irreversible Cys-PTM thus requires enrichment that
considers: (1) Cys is the second least abundant amino acid in
proteins (1.5%) (20), and (2) Cys-SO2H/SO3H are expected
to occupy only 1–2% of these Cys sites, under physiological
(and perhaps even pathological) conditions.
Specific peptide enrichment by LC followed by bottom-up
proteomics is a common approach used successfully for
many PTMs (21, 22). Limited studies, however, have explored
such techniques for Cys-SO2H/SO3H-containing peptides,
and none have examined complex lysates—only single puri-
fied proteins (23, 24). Given that these PTM are among the
most acidic modifications, with an average pKa of RSO2H  2
and RSO3H 3, it is pertinent to isolate these peptides by
exploiting their unique charge distribution. At acidic pH,
where nonmodified tryptic peptides will have an average in-
solution charge state between one and two (depending on
pKa of acidic residues and the C terminus), Cys-SO2H/SO3H-
containing peptides will have an added negative charge, and,
thus, have average charge distribution  1. Selection can
therefore be performed on either positively or negatively
charged resins with the former being a “positive” selection for
Cys-SO2H/SO3H-containing peptides (retained by the resin),
whereas the latter is a “negative” selection (Cys-SO2H/SO3H-
containing peptides will not be retained by the resin). Both
approaches have been used (23, 24) to capture peptides from
bovine serum albumin (BSA) oxidized by performic acid –
causing scission of disulfide bonds and conversion of Cys to
Cys-SO3H, and methionine (Met) to the sulfone Met(O2). The
studies gave comparative results, with positive selection (24)
increasing Cys coverage in comparison to negative selection
(23) (60% versus 45%) at the expense of specificity, with more
non-Cys peptides observed in the elution.
Ultimately, any enrichment approach must be able to purify
Cys-SO2H/SO3H-containing peptides from cells and tissues
under physiological and/or pathological conditions, both of
which will generate considerably lower levels of Cys-SO2H/
SO3H than performic acid. Myocardial ischemia and reperfu-
sion (I/R) injury is characterized by a “burst” of ROS/RNS that
is observed upon reperfusion (25, 26). These ROS/RNS over-
whelm the natural antioxidant defenses of the heart (27) and
lead to oxidative stress that contributes to contractile dys-
function (28–30). Several studies have observed an increase
in reversible Cys PTM following I/R (31–36), and an increase in
Cys-SO2H/SO3H may also contribute to cellular dysfunction
that ultimately leads to apoptosis and necrosis that follows
prolonged I/R (myocardial infarction). Given the common
practice of peptide fractionation with strong cation exchange
(SCX) as a first dimension during bottom-up proteomics, we
wished to explore its utility in identifying Cys-SO2H/SO3H
sites in complex samples. Performic oxidized BSA and myo-
cardial protein extracts were utilized to study the interactions
occurring at each step of the method, and then the method
was applied to myocardial protein extract that had been ex-
posed to a high concentration of a less efficient oxidant
(H2O2). Finally, the method was used to identify Cys-SO2H/
SO3H-containing peptides derived from either physiologically
relevant concentrations of H2O2 (i.e. 100 M, an estimate of
the likely pathological H2O2 levels (37, 38)) or from rat myo-
cardial tissue subjected to I/R injury.
EXPERIMENTAL PROCEDURES
Materials—Methanol, chloroform, potassium chloride (KCl), and
potassium/sodium dihydrogenphosphate (KH2PO4/NaH2PO4) were
purchased from Ajax Finechem (Sydney, Australia). Sequencing
grade porcine trypsin was from Promega (Madison, WI). All other
chemicals were from Sigma-Aldrich (St. Louis, MO) unless otherwise
stated. All solutions were prepared with ultrapure Milli-Q water (Mil-
lipore, Billerica, MA).
Performic Oxidation and Tryptic Digestion of BSA—Performic oxi-
dation was performed to generate Cys-SO3H as previously described
(23). Briefly, performic acid was prepared by mixing 1:19 parts H2O2
to formic acid (FA), and mixing at room temperature for 1 h. BSA (
1 mg/ml) was resuspended in FA and three volumes of performic acid
were added and the reaction incubated on ice for 2.5 h, before adding
five volumes of Milli-Q water and evaporating to dryness. The protein
was dissolved in 0.1 M NaH2PO4, pH 8, and trypsin digested for 16 h
at 37 °C with a 1:25 ratio trypsin/BSA. The digest was then concen-
trated and desalted by solid phase extraction (SPE) on hydrophilic
lipophilic balance (HLB) cartridges (Waters Corp., Milford, MA) and
the eluent evaporated to dryness.
Langendorff Perfusion—All animal studies were approved by the
Animal Care and Ethics Committee, the University of Sydney (refer-
ence: K20/4–2011/3/5517). Lewis rats (n  three per group) were
euthanized with pentobarbital (200 mg kg1), the heart rapidly ex-
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cised and subjected to Langendorff perfusion for 20 min (“baseline”
perfusion) with nonrecirculating Krebs buffer as previously described
(39), followed by either; 1) 30 min of perfusion (nonischemic time
control, NITC), or 2) 15 min of global no-flow ischemia and 15 min of
reperfusion (15I/15R). Hemodynamic data based on the rate pressure
product (RPP; a function of the heart rate in bpm  left ventricular
developed pressure [LVdev]) expressed as a percentage of baseline
showed NITC hearts were unaffected by control perfusion (RPP
105%  1% of baseline), whereas those subjected to 15I/15R recov-
ered to 66%  5% of baseline, consistent with previous studies (7,
39). Hearts were snap-frozen in liquid nitrogen and stored at 80°C.
Myocardial Native Protein Extraction and H2O2 Oxidation—Frozen
tissue (from NITC hearts) was homogenized (Omni International, Ken-
nesaw, GA) in 0.1 M NaH2PO4, pH 7, containing 1 mM phenylmethyl-
sulfonyl fluoride, 1 M aprotinin, 20 M leupeptin, and 2 mM diethyl-
enetriaminepentaacetic acid on ice. The homogenate was centrifuged
at 13,000  g for 15 min at 4 °C and the supernatant removed. H2O2
was added to the supernatant to give a final concentration of 100 nM,
10 M, 100 M, or 10 mM and incubated at room temperature for 1 h
followed by reduction with dithiothreitol (DTT) for 1 h at room tem-
perature. Proteins then underwent chloroform/methanol precipitation
to remove protease inhibitors before resuspension, trypsin digestion,
and SPE cleanup, as detailed above. Peptides/proteins were quanti-
fied by Quant-iT assay (Invitrogen, Carlsbad, CA).
Denaturing Protein Extraction from Myocardial Tissue—Frozen tis-
sue was homogenized (Omni International) in 0.1 M NaH2PO4, pH 6,
containing 20 mM N-ethylmaleimide (NEM), 1% (w/v) sodium dode-
cylsulfate, 1 mM phenylmethylsulfonyl fluoride, 1 M aprotinin, 20 M
leupeptin, and 2 mM diethylenetriaminepentaacetic acid. The homo-
genate was centrifuged at 13,000  g for 15 min at 4 °C and the
supernatant removed. Additional homogenization buffer was added
to the pellet, and the pellet underwent 2  20 s cycles of tip-probe
sonication (Branson, Darbury, CT), followed by centrifugation at
13,000  g, 15 min, 4 °C, whereupon the supernatants were pooled.
The pH was adjusted to  seven and proteins were reduced (20 mM
DTT, 1 h room temperature) and free thiols reversibly modified with
methylmethane thiosulfonate (40 mM in acetonitrile [MeCN]). Proteins
then underwent chloroform/methanol precipitation before resuspen-
sion, trypsin digestion, and SPE cleanup, as above. Peptides or
proteins were quantified by Quant-iT assay.
Performic Oxidation of Myocardial Tryptic Digest—A denatured
protein extract was prepared as above with the absence of reducing
and alkylating steps (i.e. no NEM in extraction buffer and no DTT
reduction) to preserve disulfides. Proteins then underwent chloro-
form/methanol precipitation, resuspension, trypsin digestion, and
SPE cleanup. The resultant peptides were performic oxidized as
described for BSA, and the mixture evaporated to dryness.
Strong Cation Exchange—Peptide samples (5 g BSA/25 g per-
formic oxidized extract/75 g all other samples) were diluted in 2 ml
SCX loading buffer (5 mM KH2PO4, pH 2.5) and loaded onto an SCX
cartridge (AB Sciex, Framingham, MA) equilibrated with the same
buffer (3 ml). The flow-through (FT) was collected and the cartridge
washed with an additional 1 ml SCX loading buffer, which was pooled
with the FT. The cartridge was then washed with organic wash buffer
(5 mM KH2PO4, pH 2.5, 25% MeCN) and this was collected separately
(fraction “MeCN”). Retained peptides were eluted (each 1 ml) with
varying concentrations of 100% KCl buffer (5 mM KH2PO4, pH 2.5,
25% MeCN, and 0.5 M KCl) diluted in organic wash buffer to 1, 5, 10,
15, 20, 25, 30, 40, 50, 60, 80, and 90% KCl. All fractions containing
MeCN were dried by 1⁄2 – 3⁄4 to reduce the MeCN concentration and
then diluted with 0.1% TFA to  1 ml before concentration and
desalting by SPE as above.
Offline Hydrophilic Interaction Liquid Chromatography (HILIC)—
Fractionation was performed on an Agilent 1200 series capillary LC
system (Agilent Technologies, Santa Clara, CA). Samples were resus-
pended in HILIC buffer B (90% MeCN, 0.1% triflouroacetic acid [TFA])
and separated on a home-packed column (3 m, 20 cm  320 m,
100 Å pore size) of TSKgel Amide-80 beads (Tosoh Biosciences,
Japan) using a gradient of 0–100% HILIC buffer A (0.1% TFA) for 29
min at a flow rate of 6 l min1. Between three and eight fractions
were taken depending on the individual sample complexity, judged by
spectrophotometric absorbance.
LC-MS/MS—Initial studies in BSA and performic oxidized extract
fractionated by SCX were performed on a QSTAR Elite (ABSciex,
Foster City, CA) mass spectrometer coupled online to an Agilent 1100
series nano-LC system. Follow-up studies (all SCX-HILIC fractionated
samples) were acquired on either a LTQ Orbitrap Velos (Thermo
Scientific, Weltham, MA) mass spectrometer coupled online to a
Dionex UltiMate 3000 HPLC system (Dionex, Sunnyvale, CA) or a
5600 Triple-TOF coupled online to an Eksigent nanoLC Ultra (Eksi-
gent, Dublin, CA). Samples were resuspended in buffer A (0.1% FA)
and separated on a home-packed reversed phase column (3 m, 15
cm  75 m, 120 Å pore size) of ReproSil Pur C18 AQ beads (Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany) using the following
gradients; (1) 5–40% buffer B (100% MeCN, 0.1% FA) for 105 min at
300 nL min1 (QSTAR), (2) 0–45% buffer B2 (90% MeCN, 0.1% FA)
for 50 min at 250 nL min1 (LTQ Orbitrap Velos), or (3) 2–35% buffer
B for 45 min at 300 nL min1 (5600). All MS instruments were oper-
ated in data-dependent positive ion mode with an m/z range of
300–2000. For the QSTAR and 5600, the top five and 15 most intense
precursor ions with charge states 2	 to 4	 were selected for colli-
sion-induced dissociation (CID) fragmentation, respectively. For the
LTQ Orbitrap Velos, the four most intense ions with charge states 2	
to 4	 were selected for both higher energy collisional dissociation
(HCD) and CID fragmentation, in an alternating manner (i.e. eight
MS/MS per MS for four precursors). Dynamic exclusion was enabled
with windows of 30 s (QSTAR and Orbitrap) or 10 s (5600). Raw data
were scripted to .mgf in Mascot Distiller (vers. 2.4.3.3; Matrix Science,
London, UK).
Data Analysis—Performic oxidized peptide data were searched
against the UniProt database (BSA) or UniProt Rattus norvegicus
database (taxonomy number 10116; release 2013_11) using an in-
house Mascot server (vers. 2.4). Parameters were one missed cleav-
age, variable modifications: Met(O2), and Cys(O3), pyroglutamate
(pyroGlu) at Q/E, acetyl (protein N terminus). The modification phos-
pho (ST) was utilized for initial performic oxidized extract searches to
judge levels of enrichment of contaminating phosphopeptides on
HILIC. H2O2 oxidized myocardial peptide data were searched against
the UniProt R. norvegicus database, as above with the addition of the
variable modifications; Cys(O2), Cys(O3), Met(O), and without pyroGlu
at E and phospho (ST) as these were not major contaminants in the
SCX-HILIC fractions. Nonoxidized (denatured protein extract) myo-
cardial peptide data (H2O2, NITC, and I/R samples) were searched as
for H2O2-oxidized peptides with the addition of the variable modifi-
cations: NEM (C) and methylthio (C). Because the Cys-SO2H (	32 Da)
and Cys-SO3H (	48 Da) modifications are of mass that could be
confused with several oxidative amino acid modifications (e.g. hy-
droxyproline, N-formylkynurenine etc. (40)) or in a doubly modified
peptide equal phosphorylation (32 	 48  80 Da), we searched our
data including these modifications. Peptides identified with these
modifications at MASCOT ion scores equal or higher than those
obtained when including Cys-SO2H and SO3H were excluded from
subsequent analysis. Instrument-dependent peptide/fragment toler-
ances of searches were; 0.2 Da/0.2 Da (QSTAR), 10 ppm/0.1 Da
(Orbitrap Velos), and 50 ppm/0.1 Da (5600). Samples from H2O2-
treated proteins, NITC and 15I/15R hearts were subjected to three
separate SCX enrichments followed by HILIC separation. Each of the
resulting FT and MeCN fractions were analyzed by LC-MS/MS as
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described above. All searches were performed against a decoy da-
tabase and filtered to a  2% false discovery rate (FDR). Peptides
containing irreversible Cys modifications were accepted based on
significant MASCOT scores. Because the numbers of peptides con-
taining Cys-SO2H or SO3H modifications were relatively low, those
identified in only a single replicate were subjected to manual anno-
tation of their corresponding MS/MS spectra, according to the criteria
as established by (41), to confirm the identification as provided by
MASCOT. Reproducibility of the fractionation technique for myocar-
dial peptides is shown in supplemental Table S4A–4F. Representative
MS/MS spectra of identified Cys-SO2H and -SO3H-containing pep-
tides from rat myocardial tissue subjected to NITC, H2O2 treatment,
and 15I/15R are contained in supplemental Data S1.
Bioinformatics—Gene Ontology (GO) terms were obtained via input
of UniProt identifiers into the DAVID bioinformatics tool (42) with a
background reference of all GO terms from R. norvegicus. Values
were obtained for fold over-representation and modified Fisher Ex-
tract calculation (43) and used to rank the results for functional
clustering.
RESULTS AND DISCUSSION
Modified SCX Strategy for the Negative Selection of Perfor-
mic Oxidized Cys—A common SCX strategy is to bind pep-
tides in a low pH aqueous mobile phase containing low salt
and a percentage of organic solvent, most typically MeCN at
20–30% (v/v). The latter condition is included to limit hydro-
phobic retention of peptides, and, thus, increase orthogonal-
ity when coupled to reverse phase separation. A mobile phase
pH of 2.5–3 (most commonly used) however, is within the
average pKa range of Asp (3.5  1.2) and the C terminus
(3.3  0.8) in proteins (44). It is estimated that many more
peptides not containing Cys-SO2H/SO3H will be neutral at
this pH than previously thought (23) – even in the absence of
biological PTM (e.g. amine acetylation, protein cleavage etc.).
Retention of neutral peptides by the SCX resin via hydropho-
bic forces would thus be advantageous to increase the neg-
ative selection of Cys-SO3H peptides from complex mixtures
containing unmodified peptides with neutral charge.
SCX (pH 2.5) of performic oxidized BSA peptides in the
absence of an organic modifier allowed the identification of 20
Cys-SO3H sites on 14 peptides in the “flow-through” (FT),
with 67% of these peptides containing a Cys-SO3H (14/21
peptides) and the remainder constituting either nontryptic
cleavages or the protein C terminus (supplemental Table S1).
When 25% (v/v) MeCN was included in the mobile phase, only
one additional Cys-SO3H site was identified but nine addi-
tional unmodified peptides were present, and only 30%
peptides contained Cys-SO3H. This indicates that the initial
binding of peptides in aqueous buffer to obtain the FT fraction
and then performing a subsequent wash with buffer contain-
ing an organic modifier, is advantageous in depleting hydro-
phobic/neutral peptides from the FT. An additional nine Cys-
SO3H BSA peptides were recovered in the 15% (w/v) KCl
wash with 48% of peptides in this fraction containing the
modification. All Cys-SO3H peptides observed here contained
an additional charged residue arising from a His (nine pep-
tides), a missed cleavage (one peptide), or an Arg/Lys fol-
lowed by Pro, (R/K)-P, which is not cleaved by trypsin (four
peptides). No additional sites were observed at higher con-
centrations of KCl. Overall, 86% of Cys sites in BSA were
identified as Cys-SO3H, which is an improvement over previ-
ous methods that observed 45% (23) and 60% (24),
respectively.
To investigate the method in a complex biological sample,
we performed performic oxidation of a myocardial protein
digest. Initially, an extended SCX gradient of 16 steps (sup-
plemental Table S2) was performed to allow for the clustering
of similarly charged peptides into fractions and thus avoid
dilution of peptide signals (supplemental Fig. S1). It was then
possible to categorize six charge distributions (Fig. 1A) and
these [KCl] were used for all further SCX fractionations. The
FT distribution was the only fraction skewed to the left (neg-
atively charged) indicating electrostatic repulsion of some
peptides from the resin. The organic wash (MeCN) fraction
contained primarily neutral peptides, which are most likely
retained by noncharge mediated interactions (i.e. dispersive).
Calculations of the Kyte-Doolittle hydrophilicity (45) (estimat-
ing the hydrophilicity value of Cys-SO3H to be equivalent to
Arg) showed that peptides in the FT were more hydrophilic
than those in the MeCN wash (average hydrophilicity of 8.3
and 2.3, respectively). Given that both fractions appear
relatively hydrophilic, we attempted to increase the elution of
hydrophobic peptides by increasing the organic content to
50%; however, this did not increase the number of peptides
eluting in this fraction (data not shown). All SCX elution steps
(1–100% KCl) could be subdivided into four charge distribu-
FIG. 1. Resolution of Cys-SO3H peptides from performic oxi-
dized myocardial extract by SCX. A, In-solution charge distributions
of peptides across the six summed SCX fractions, plotted as percent
of PSMs for each fraction; B, Unique peptides as a percent of total
identifications occurring in all fractions, plotted for total peptides and
Cys-SO3H peptides, across the six SCX fractions; C, Cys-SO3H,
pyroglutamate, acetyl-modified, and unmodified peptides as a per-
cent of total identified peptides in each fraction.
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tions (10%, 25%, 40, and 100%, which reflect the highest KCl
concentrations demonstrating a distribution; Fig. 1A). The
1–10% (“10%”) KCl distribution contains almost entirely sin-
gly charged peptides and the higher [KCl] fractions contain
increasingly positively charged peptides.
The complexity of the samples, measured as the percent-
age of total unique peptide identifications found in each frac-
tion (Fig. 1B), indicated that the most complex were the salt
elutions with 84% of identifications arising from these frac-
tions. A similar plot, however, for unique Cys-SO3H identifi-
cations as a percentage of the total (Fig. 1B) indicated that the
initial fractions contain 71% of the identified Cys-SO3H pep-
tides – indicating good selection of these peptides into the
relatively lower complexity FT and MeCN fractions (supple-
mental Table S2). Generally, we observed that the FT was
more enriched in Cys-SO3H peptides (Fig. 1C), with 72% of
identifications containing this modification, in comparison to
the MeCN fraction with 43% of identifications. All salt frac-
tions displayed a lower percentage of Cys-SO3H peptides,
with fewer than 15% of identifications containing the modifi-
cation and the majority of these (55%) were contained in the
10% KCl fraction. Many of the nonoxidized peptides in the FT
and MeCN fractions contained PTM, such as amine acetyla-
tion (protein N terminus) and cyclization of the peptide N
terminus at Glu and Gln to form pyroGlu. These PTM reduce
the in-solution charge of these peptides and result in them not
being retained by the resin. It could be argued that these PTM
also make the peptides more hydrophobic, and this may be
why a greater percentage is observed in the MeCN fraction.
Because methionine can also be oxidized to methionine sulf-
oxide (MetOx) and methionine sulfone (MetO2), we examined
the data to determine whether these Met-peptides were en-
riched using our approach. We observed no evidence of their
enrichment in FT or MeCN fractions post-SCX, which was
expected as the oxidative modification of Met does not the-
oretically alter charge, and thus, would not be expected to
alter retention and elution from SCX chromatography. All
salt fractions contained predominantly unmodified tryptic
peptides.
Positive Selection by HILIC Improves Cys-SO3H Peptide
Identification—Given that the predominant contaminating
peptides in the FT and MeCN fractions are N-terminal modi-
fications that are expected to decrease hydrophilic interac-
tions, we explored the use of HILIC to further enrich for
Cys-SO3H-containing peptides in performic oxidized myocar-
dial extracts (supplemental Table S3). Cys-SO3H-modified
peptides fractionated by SCX (FT, MeCN) retain well on HILIC,
which is denoted by increased peptide spectral matches
(PSMs) to these peptides in HILIC fractions containing in-
creased aqueous composition (Fig. 2A), whereas other pep-
tides were relatively depleted. The possible exceptions are
phosphopeptides, which are relatively sparse contaminants in
early SCX fractions (10% of PSMs in FT and MeCN), in
comparison with N-terminally modified and unmodified tryptic
peptides (20–30% of PSMs). Prior treatment of samples
with phosphatases would reduce this effect; however, we
chose to limit the number of sample handling steps consid-
ering the relatively minor effect phosphopeptides have on the
final analysis (Fig. 2A). It was noted that the complete elution
of Cys-SO3H peptides in the FT fraction required a higher
percent aqueous phase than the MeCN fraction, necessitating
the use of 48 and 43% H2O, respectively. This again high-
lights the difference in the population of these two SCX frac-
tions; even after HILIC fractionation we only observed 15% of
the total and 16% of the Cys-SO3H peptide matches as
shared between SCX FT and MeCN fractions (supplemental
Table S3).
The HILIC strategy does not aid in the further enrichment of
Cys-SO3H peptides that fractionate by SCX into the salt frac-
tions (supplemental Fig. S2A). These fractions contain many
basic peptides that, like Cys-SO3H peptides, will retain well
on HILIC, and are of much higher abundance in the sample.
FIG. 2. HILIC separation positively
selects for Cys-SO3H-containing pep-
tides post-SCX negative selection. A,
Percent total PSMs arising from unmod-
ified/modified peptides with increasing
aqueous phase; B, percentage of total
Cys-SO3H peptide identifications arising
from FT, MeCN, and 10% KCl fractions
following HILIC enrichment. Inset shows
the subdivision of peptides contained
within the 10% KCl fraction by whether
they are His-containing or contain a
missed cleavage/(R/K)-P site.
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The extra dimension of chromatography, however, does in-
crease coverage of Cys-SO3H sites in the 10% KCl fraction,
which comprises 10% of the identified peptides. This frac-
tion contains 15% of unique Cys-SO3H identifications (Fig.
2B) and this peptide population almost all contain an addi-
tional positively charged residue in their sequence. This is
most commonly His (58%), but may also be the result of a
missed cleavage (7%) or a (R/K)-P site (20%). Subsequent
salt fractions were much less informative with 1% of unique
Cys-SO3H peptides observed in these fractions combined.
Given this lack of additional site information it was decided
that further analysis would concentrate on FT, MeCN, and
10% KCl SCX fractions. A general schematic of the developed
method is presented in Fig. 3.
Enrichment of Cys-SO2H/SO3H Modifications in H2O2 Oxi-
dized Myocardial Extract—Performic acid is a much stronger
oxidant than proteins will ever encounter biologically, result-
ing not only in the oxidation of thiols but also the scission of
disulfides, which are otherwise relatively inert to oxidation,
and, thus complete reaction to Cys-SO3H. A more common
path to Cys-SO3H is sequential oxidation via Cys-SOH and
Cys-SO2H, which is the pathway for oxidants such as H2O2.
This is a much less efficient reaction and will thus result in the
formation of fewer irreversible modifications that will include
both Cys-SO2H and Cys-SO3H. Therefore, we tested the
protocol with myocardial protein extracts that had been oxi-
dized with a high concentration of H2O2 (10 mM). A native
protein sample was chosen for oxidation so as to: (1) preserve
any Cys reactivity designated by three-dimensional structure
(e.g. Prx), which is not present once denatured; and (2) to
prevent oxidation of sites that are not normally accessible to
H2O2.
Following SCX-HILIC fractionation and LC-MS/MS (Fig. 3),
we observed 119 peptides containing irreversibly oxidized
Cys with 14 observed as Cys-SO2H, 76 as Cys-SO3H, and 29
in both forms (supplemental Table S4). The Cys-SO2H/SO3H
peptides observed following 10 mM H2O2 oxidation fraction-
ate similarly to the performic oxidized peptides, with 53% of
unique Cys-SO2H/SO3H peptides first observed in the FT, an
additional 39% observed in the MeCN fraction, and only 8%
in the 10% KCl fraction (Fig. 4A), despite more extensive
fractionation of the 10% KCl fraction (compared with FT and
MeCN) in an attempt to increase site observation. Cys-SO2H/
SO3H peptides from 10 mM H2O2-treated proteins also retain
well on HILIC; however, because of their low abundance,
were never a majority population, representing at most 6–8%
of unique PSMs (Fig. 4B). This is not, however, a trivial level of
FIG. 3. Schematic of SCX-HILIC method for the enrichment of
irreversibly oxidized Cys (oxCys)-containing peptides. Initial bind-
ing of peptide samples by SCX chromatography in an aqueous buffer
allows for electrostatic repulsion of peptides containing oxCys and
their negative selection into the FT fraction. Subsequent washing with
an aqueous phase containing an organic modifier will liberate hydro-
phobic and neutral oxCys peptides retained by the resin along with an
increasing amount of neutral non-oxCys peptides (e.g. PTM pep-
tides). Elution with a low salt concentration will elute retained oxCys
peptides containing basic residues (H/K/R), as well as singly charged
tryptic peptides, whereas increased salt concentrations will elute
increasingly positive tryptic peptides. oxCys peptides from the initial
fractions may be positively selected by HILIC chromatography where
they are retained later than more hydrophobic PTM peptides.
FIG. 4. Fractionation of peptides generated from myocardial
extract oxidized by 10 mM H2O2. A, Percent total unique and unique
Cys-SO2H/SO3H peptides identified in each fraction; B, PSMs corre-
sponding to Cys-SO2H/SO3H peptides enriched with increased aque-
ous phase by HILIC, with the percent total representing the average
over all fractions.
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enrichment as these PTM are estimated to be present at2%
of Cys residues (14), whereas N-terminal acetylation for ex-
ample occurs at many, if not most, protein N termini. Again,
the largest contaminants were these acetylated protein N
termini, as well as N-terminal pyroGlu and unmodified tryptic
or nontryptic peptides (e.g. protein C termini). It is worth
noting that with the increased total peptide loading that is
necessary to observe Cys-SO2H/SO3H in 10 mM H2O2-
treated samples (which is still less than the binding capacity of
the resin), decreased retention of acidic peptides was ob-
served, particularly in the MeCN fraction, with 51% of unmod-
ified peptides containing two or more acidic residues in their
sequence. Reduction of loading and wash volumes, to pre-
vent increased hydrophilic partitioning at higher loads, did not
reduce this effect (data not shown). It would therefore be best
to utilize a column with a much higher loading capacity (100
g) as it would likely reduce this effect and allow for the
increased observation of low abundance sites.
The biological range for H2O2 concentration ([H2O2]) is a
point of considerable conjecture, but the general range of
physiologically relevant concentrations is thought to be 1–700
nM (37) with an upper limit of 1–15 M measured in some
tissues (38), whereas the pathological concentrations are not
thought to exceed 200 M (38). Thus, measurements made
above these levels are unlikely to be directly physiologically
relevant and may result in the oxidation of relatively unreactive
sites. To better reflect the physiological and pathological
range of H2O2 concentrations, isolation of irreversibly oxi-
dized Cys-containing peptides was undertaken from rat myo-
cardial proteins exposed to 100 nM, 10 M, and 100 M H2O2.
At 100 nM, 52 sites were observed (Fig. 5A and supplemental
Table S4) with nine Cys-SO2H, 27 Cys-SO3H and 16 Cys-
SO2H/SO3H sites. At higher [H2O2] this increased, with 72
observed at 10 M H2O2 (10 Cys-SO2H, 35 Cys-SO3H, and 27
Cys-SO2H/SO3H) and 86 sites at 100 M H2O2 (14 Cys-SO2H,
49 Cys-SO3H, and 23 Cys-SO2H/SO3H). In total, 105 sites
were observed across all H2O2 concentrations, with a large
number (40 sites) observed across all three (Fig. 5B and
supplemental Table S4). Many unique sites were also ob-
served in lysates exposed to 100 M H2O2 alone, or were
shared between the 10 M and 100 M concentrations.
By increasing prefractionation steps we were able to ob-
serve an increase in coverage of the irreversible Cys proteome
even when measuring sites produced at [H2O2] less than a
quarter of those applied in other studies (19). The main reason
for advocating a method with no prefractionation would be to
decrease artifacts, but as all chromatography techniques are
performed at acidic pH (3) and on peptides, artifact gener-
ation is much more likely to occur during extraction and
digestion than prefractionation. To couple this method to site
determination in tissues that are not treated with exogenous
oxidants, care should be taken to avoid formation of artifacts
by performing extractions at low pH, in solutions containing
strong denaturants (e.g. detergents), low pH alkylating agents
(46), and metal ion chelators. Protease inhibition is of high
importance, as the method is particularly sensitive to nontryp-
tic proteolysis occurring at any stage in the protocol. Con-
versely, the method will also be sensitive to incomplete tryptic
cleavage, which will increase the percentage of Cys-SO2H/
SO3H sites eluting in the SCX salt fractions. To ensure low
levels of missed tryptic cleavages, increased trypsin/protein
ratios can be utilized for digestion. Unfortunately, increasing
pH, reaction time and temperature of digestion will also lead
to increased formation of pyroGlu at N termini. Any increased
contamination of the FT/MeCN fractions by pyroGlu peptides
should be endured as the chance of resolving correctly
cleaved Cys-SO2H/SO3H from pyroGlu in these fractions by
HILIC is much higher than resolving missed cleaved Cys-
SO2H/SO3H peptides from unmodified tryptic peptides in
SCX salt fractions.
Enrichment of Cys-SO2H/SO3H Modifications Following
Myocardial I/R Injury—Protein extracts/cells treated with ex-
ogenous oxidants remain a questionable model of pathology.
Thus, we sought to decipher whether the method could be
applied to myocardial tissue subjected to pathologically rele-
vant I/R injury via Langendorff perfusion. I/R injury is associ-
ated with acute oxidative stress, particularly during early rep-
erfusion, and which is thought to generate oxidative protein
FIG. 5. Cys-SO2H/SO3H-containing peptide identifications in
myocardial extracts oxidized by differing [H2O2] and in myocar-
dial tissue subjected to Langendorff perfusion (NITC and I/R). A,
Number of sites observed in each sample, with total sites, Cys-SO2H
and Cys-SO3H sites denoted; B, overlap of Cys-SO2H/SO3H sites
identified at 100 nM, 10 M, and 100 M H2O2.
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damage leading to contractile dysfunction and eventually
apoptosis and necrosis. We performed enrichment of Cys-
SO2H/SO3H-containing peptides from rat myocardium sub-
jected to either 30 min of control perfusion (“nonischemic time
control”; NITC) or 15 min no-flow ischemia with 15 min rep-
erfusion (15I/15R; I/R). From the NITC extract we observed 24
sites; five Cys-SO2H, 17 Cys-SO3H and two Cys-SO2H/SO3H
sites (Fig. 5A and supplemental Table S4). Following I/R, the
number of observed sites increased threefold (84 sites;
eight Cys-SO2H, 49 Cys-SO3H, and 27 Cys-SO2H/SO3H
sites). Of the 24 sites identified in NITC samples, 15 were
identified in the samples subjected to I/R. Although we did not
perform quantitative analysis (label-based), several of these
peptides were observed in I/R in both the SO2H and SO3H
forms, potentially indicating a larger proportion of the protein
pool is irreversibly oxidized. Additionally, we examined iden-
tifications from the FT, MeCN, and KCl fractions to determine
whether the increase in irreversibly oxidized Cys-peptides in
15I/15R was also reflected in a change in the ratio of unmod-
ified/reversibly modified Cys-peptides between NITC and 15I/
15R. Our sample preparation protocol uses NEM to alkylate
unmodified Cys thiols and then subsequent DTT/MMTS treat-
ment to reduce and alkylate Cys peptides containing Cys in a
reversibly modified form. We interrogated the data to examine
peptides containing Cys-NEM modification (unmodified Cys-
peptides) and Cys-methylthio modification (reversibly modi-
fied Cys-peptides). In NITC hearts, 128 (26.1% of all identified
Cys-peptides) Cys-containing peptides were reversibly mod-
ified and 339 (69.0%) were unmodified, whereas following
15I/15R we identified 243 (38.0%) reversibly modified Cys-
peptides and 313 (48.9%) that were unmodified (data not
shown), which is consistent with the more oxidizing environ-
ment during I/R injury. It was noted that many of the sites
observed as irreversibly oxidized following I/R were also ob-
served in H2O2-treated extracts (62% overlap; Table I), indi-
cating that these may be pathologically relevant, and site
identification numbers were very similar to those observed for
the 100 M H2O2 sample (Fig. 5A). In NITC tissue, the overlap
to H2O2-treated extracts was 42%, with the unique peptides
largely representing myofilament/cytoskeletal proteins, which
were not observed in H2O2 treated samples, most likely be-
cause of their low solubility in aqueous solutions without
denaturants.
Irreversible protein oxidation, particularly of myofilament
proteins, has been suggested as a potential cause of de-
creased myocardial contractility following I/R (33, 35, 47, 48).
The myofilament or cytoskeleton does appear to be a site of
irreversible Cys oxidation, with seven Cys-SO2H/SO3H sites
contained on six myofilament/cytoskeletal proteins in NITC
samples, and increasing to 17 sites on 12 proteins following
I/R (Table I and supplemental Table S4). When functional
clustering was performed (supplemental Fig. S3), several
other clusters were also observed as over-represented. The
most over-represented cluster contains mitochondrial pro-
teins, likely because of both the role of mitochondria in oxi-
dant generation and also their high abundance in myocardial
tissue. The second over-represented cluster were oxi-
doreductases, as their role in electron transport likely makes
them susceptible to oxidation, particularly those proteins con-
taining metal centers or those involved in the detoxification of
oxidants (e.g. Prx). Further sub-clustering indicates energy
utilization pathways are over-represented (Table I), including
proteins involved in glycolysis (6/9 enzymes), the citrate cycle
(6/7 enzymes), electron transport chain (ETC)/ATP synthase
(nine proteins), and fatty acid/amino acid metabolism (13 pro-
teins). Interestingly, we observed their Cys oxidation state
across NITC and I/R to be quite distinct. Although glycolytic
enzymes contain Cys-SO2H/SO3H modifications even in NITC
tissue, citrate cycle enzymes, and electron transport/ATP syn-
thase enzymes were almost only ever observed to contain
Cys-SO2H/SO3H modifications following I/R (or H2O2 treat-
ment). This may be because of their differing subcellular lo-
calization, that is, cytoplasmic versus mitochondrial, but a
similar trend was not observed for proteins involved in fatty
acid or amino acid metabolism, many of which are also lo-
cated in the mitochondria and are still observed as oxidized in
NITC tissue.
Over all the conditions studied (NITC, I/R, and H2O2 treat-
ment), 181 Cys-SO2H/SO3H sites were observed, which con-
stitutes the largest number of irreversibly modified Cys sites
currently revealed in the literature. Interestingly, 30–50% of
total site identifications under each condition contained Cys-
SO2H, whereas substantially more (70–80%) could be mon-
itored in the Cys-SO3H form (Fig. 5A). This may be because:
(1) Cys-SO2H is more efficiently oxidized to Cys-SO3H than
Cys-SOH is to Cys-SO2H; or (2) Cys-SO3H gives better spec-
tral characteristics for assignment. The observation that the
Cys-SO2H peptide percentage of total Cys-SO2H/SO3H iden-
tifications negatively correlated with [H2O2] may indicate that
the former is a possibility (with I/R sitting in between 10 and
100 M H2O2 samples). Although, as the NITC samples had
the lowest Cys-SO2H % of total Cys-SO2H/SO3H identifica-
tions (similar to 10 mM H2O2) this may indicate that spectral
assignment at low intensities may be better for Cys-SO3H.
Our technique is, however, likely to be poorly compatible
with iTRAQ/tandem mass tags (TMT) as these add an extra
charge for every N terminus and Lys modified. This essentially
shifts all peptide in-solution charge states up by two for every
peptide ending with Lys, and one for those ending in Arg. It is
this factor (Lys versus Arg peptide charge) that causes co-
elution of Arg peptides with some containing Cys-SO2H/
SO3H (those ending in Lys or containing His), which will have
the same in-solution charge but are of vastly lower abun-
dance. Thus, quantitative analysis of these modifications is
likely to be most successful by independent sample analysis
using label-free quantitation (e.g. spectral counting), MS pre-
cursor area, or for those compatible cell and tissue types,
label-based quantitation that does not alter the charge or
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TABLE I
Summary of Cys-SO2H/SO3H peptides observed in Langendorff perfused myocardial tissue (NITC, I/R) compared with H2O2-treated myocardial
samples. Proteins that contain Cys-SO2H/SO3H PTM were clustered by biological function. Sites were observed as shown, with the numbers
indicating observation of: 
2
 sulfinic acid, 
3
 sulfonic acid, 
2,3
 both forms independently, 
(2/3)
 both forms on the same peptide (doubly modified
peptide). ** Indicates the site was observed in the 10 mM H2O2 concentration only. All identifications are provided in supplementary Table S4
Cys-SOnH
(n  2 or 3)
Protein Identifier Protein Description Peptide Sequence NITC I/R H2O2
GLYCOLYSIS/GLUCOSE METABOLISM
ALDOA_RAT Fructose-bisphosphate aldolase A ALANSLACQGK 2,3 2,3
TPIS_RAT Triosephosphate isomerase CLGELICTLNAAK 3 3 2,3
IAVAAQNCYK 3 3
IIYGGSVTGATCK 3
G3P_RAT Glyceraldehyde-3-phosphate
dehydrogenase
VPTPNVSVVDLTCR 3 2,3 2,3
F1M3E5_RAT Uncharacterized protein (Glyceraldehyde-3-
phosphate dehydrogenase family)
IVSNASGITNCLAPLAK 2 2,3 2
M0R4Q0_RAT Uncharacterized protein (Glyceraldehyde-3-
phosphate dehydrogenase family)
IIVSNASCTTNCLAPLAK 3 2,3
ENOB_RAT Beta enolase VNQIGSVTESIQACK 2,3 2,3
D4ADU8_RAT Pyruvate kinase KLHATCAEGIDVAK 2 2
KPYM_RAT Pyruvate kinase PKM AEGSDVANAVLDGADCIMLSGETAK 3 3
LDHA_RAT L-Lactate dehydrogenase A chain VIGSGCNLDSAR 2,3 2,3
CITRIC ACID CYCLE
ODPB_RAT Pyruvate dehydrogenase E1 component
subunit beta
EGIECEVINLR 3 3
CISY_RAT Citrate synthase, mitochondrial LPCVAAK 2,3 2,3
ACON_RAT Aconitate hydratase, mitochondrial VGLIGSCTNSSYEDMGR 3 2,3 2,3
IDHP_RAT Isocitrate dehydrogenase NADP,
mitochondrial
CATITPDEAR 2,3 2,3
VCVQTVESGAMTK 2,3 2,3
DHSA_RAT Succinate dehydrogenase ubiquinone
flavoprotein subunit
VGSVLQEGCEK 3 3
MDHC_RAT Malate dehydrogenase, cytoplasmic ENFSCLTR 3 3
VIVVGNPANTNCLTASK 2,3 2,3
MDHM_RAT Malate dehydrogenase, mitochondrial EGVIECSFVQSK 3 2,3 2,3
ETECTYFSTPLLLGK 2,3 2,3
GCDVVVIPAGVPR 2,3 2,3
GYLGPEQLPDCLK 3 2,3
ELECTRON TRANSPORT/ATP
SYNTHESIS
ATP5H_RAT ATP synthase subunit d, mitochondrial NCAQFVTGSQAR 2,3 2,3
ATP5E_RAT ATP synthase subunit epsilon,
mitochondrial
FSQICAK 3
ETFA_RAT Electron transfer flavoprotein subunit alpha,
mitochondrial
LGGEVSCLVAGTK 3 2,3
QCR1_RAT Cytochrome b-c1 complex subunit 1,
mitochondrial
LCTSATESEVTR 3 2,3 2,3
YFYDQCPAVAGYGPIEQLSDYNR 2,3**
QCR2_RAT Cytochrome b-c1 complex subunit 2,
mitochondrial
NALANPLYCPDYR 3 2,3
COX5B_RAT Cytochrome c oxidase subunit 5B,
mitochondrial
CPNCGTHYK 3
B2RYW3_RAT NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 9
AFCAPPAYLTHR 3 3
NDUS1_RAT NADH ubiquinone oxidoreductase 75 kDa
subunit
AVTEGAQAVEEPSIC 3
FATTY ACID/AMINO ACID METABOLISM
ACADS_RAT Short-chain specific acyl-CoA
dehydrogenase, mitochondrial
IGCFALSEPGNGSDAGAASTTAR 3 3 3**
IGIASQALGIAQASLDCAVK 3
ACADV_RAT Very long-chain specific acyl-CoA
dehydrogenase
SSAVPSPCGK 2,3 2,3
ACADL_RAT Long-chain specific acyl-CoA
dehydrogenase
CIGAIAMTEPGAGSDLQGVR 2,3 2,3
ACADM_RAT Medium-chain specific acyl-CoA
dehydrogenase
MTEQPMMCAYCVTEPSAGSDVAGIK 2,3
ECHM_RAT Enoyl-CoA hydratase, mitochondrial TFQDCYSGK 3 3
THIL_RAT Acetyl-CoA acetyltransferase, mitochondrial QATLGAGLPIATPCTTVNK 3 3
MCAT_RAT Carnitine/acylcarnitine carrier protein CLLQIQASSGK 3
AATC_RAT Aspartate aminotransferase, cytoplasmic SCASQLVLGDNSPALR 2,3 2,3
AATM_RAT Aspartate aminotransferase, mitochondrial TCGFDFSGALEDISK 3 2,3 2,3
VGAFTVVCK 3 3
MMSA_RAT Methylmalonate-semialdehyde
dehydrogenase
CMALSTAVLVGEAK 2 2,3 2,3
VCNLIDSGAK 3 2,3**
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hydrophilicity of peptides (e.g. stable isotope labeling by
amino acids in cell culture [SILAC]). Additionally, the obser-
vation of Cys-SO2H/SO3H peptides is made much harder by
their extremely low abundance and hence site stoichiometry
of reduced/reversibly oxidized/irreversibly oxidized forms
may only be possible via techniques such as oxMRM (49),
which specifically target a small subset of sites for label-free
quantitation, but requires prior knowledge of the modified
sites. Recent work has tried to eliminate some of these
problems for nonmodified/reversibly modified redox sites
by employing cysTMTRAQ (50) to determine changes in
redox-modified peptide abundance with respect to protein
turnover.
To our knowledge, this is also the only proteomics study to
enrich Cys-SO2H/SO3H-containing peptides from tissue,
which had not been subjected to exogenous oxidant addition.
TABLE I—continued
Cys-SOnH
(n  2 or 3)
Protein Identifier Protein Description Peptide Sequence NITC I/R H2O2
DCMC_RAT Malonyl-CoA decarboxylase, mitochondrial TPAPAEGQCADFVSFYGGLAEAAQR 3
ALDH2_RAT Aldehyde dehydrogenase, mitochondrial LLCGGGAAADR 3 2
FABP4_RAT Fatty acid-binding protein CDAFVGTWK 3 2,3
MYOFILAMENT/CYTOSKELETON
ACTC_RAT Actin, alpha cardiac muscle 1 CDDEETTALVCDNGSGLVK 2,3 2
ACTA_RAT Actin, aortic smooth muscle MCEEEDSTALVCDNGSGLCK (2/3)
ACTB_RAT Actin, cytoplasmic 1 DDDIAALVVDNGSGMCK 3
LLCYVALDFEQEMATAASSSSLEK 2,3
ACTG_RAT Actin, cytoplasmic 2 EEEIAALVIDNGSGMCK 3 3
MEEEIAALVIDNGSGMCKAGFAGDDAPR
ACTH_RAT Actin, gamma enteric smooth muscle CEEETTALVCDNGSGLCKAGFAGDDAPR 2
MCEEETTALVCDNGSGLCKAGFAGDDAPR (2/2)
CAPZB_RAT F-actin capping protein subunit beta MSDQQLDCALDLMR 3
MYL3_RAT Myosin light chain 3 ITYGQCGDVLR 3 3 3
LMAGQEDSNGCINYEAFVK 3
MYH10_RAT Myosin 10 KDQSILCTGESGAGK 3 3
MYH6_RAT Myosin 6 CIIPNER 2 3
CNGVLEGIR 2
MYPC_RAT Myosin-binding protein C, cardiac-type DQAVFKCEVSDENVR 3
MYO1E_RAT Unconventional myosin Ie ENQCVIISGESGAGK 3
TPM1_RAT Tropomyosin alpha-1 chain CAELEEELK 2,3
VIME_RAT Vimentin QVQSLTCEVDALK 3
ION TRANSPORT
IRK11_RAT ATP sensitive inward rectifier potassium
channel 11
LCFMLR 3
ADT1_RAT ADP/ATP translocase 1 EFNGLGDCLTK 2,3 2,3
GADIMYTGTVDCWR 3 2**,3
ADT2_RAT ADP/ATP translocase 2 YFAGNLASGGAAGATSLCFVYPLDFAR 3
AT2A2_RAT Sarcoplasmic/endoplasmic reticulum calcium
ATPase 2
VGEATETALTCLVEK 3 2**,3
AT2A3_RAT Sarcoplasmic/endoplasmic reticulum calcium
ATPase 3
CGQFDGLVELATICALCNDSALDYNEAK 3
MPCP_RAT Phosphate carrier protein, mitochondrial GWAPTLIGYSMQGLCK 3 3
RESPONSE TO STRESS/HYPOXIA/ROS
HSPB8_RAT Heat shock protein beta 8 ADGQLPFPCSYPSR 3
CH60_RAT 60 kDa heat shock protein, mitochondrial AAVEEGIVLGGGCALLR 3 3
PRDX5_RAT Peroxiredoxin 5, mitochondrial GVLFGVPGAFTPGCSK 3 3 3
PRDX6_RAT Peroxiredoxin 6 DFTPVCTTELGR 3 3 2,3
D4ADD7_RAT Glutaredoxin 5 homolog (Predicted), isoform
CRA
GTPEQPQCGFSNAVVQILR 3 2**,3
VARIOUS FUNCTIONS/FUNCTION
UNKNOWN
RS28_RAT 40S ribosomal protein S28 TGSQGQCTQVR 3
KCRM_RAT Creatine kinase M-type FCVGLQK 3 3
KCRS_RAT Creatine kinase S-type, mitochondrial LGYILTCPSNLGTGLR 2,3 2,3
CFAI_RAT Complement factor I SGVCIPNQR 3 3
ES1_RAT ES1 protein homolog, mitochondrial KPIGLCCIAPVLAAK 3 3
MUC2_RAT Mucin 2 GRCVPLSK 2 2
HBB1_RAT Hemoglobin subunit beta 1 EFTPCAQAAFQK 3 3 2,3
D3ZA85_RAT Histone cell cycle regulation defective
interacting protein 5
LQGSCTSCPSSIITLK 3
G3V8S8_RAT Oxysterol-binding protein DGFCMSGSITAK 3
NHRF2_RAT Na	/H	 exchange regulatory cofactor NHE-
RF2
QLTCTEEMAHR 2,3 3
D3ZQW1_RAT Protein Blm CSSMLKDLDDSDK 2
E9PT83_RAT Protein Cenpf LECMLSECTALCENK (2/3)
D3ZSE6_RAT Protein Dfnb59 RETVYGCFQCSVDGVK 3
E9PU13_RAT Protein Snx4 EYLFYAEALRAVCR 2
F1LU05_RAT Uncharacterized protein SYEQQCIEELR 2
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The sites observed agree well with sites that are known to be
reversibly Cys modified under various conditions (7), indicat-
ing that multiple PTMs occur at these Cys sites, including
both reversible and irreversible forms. Comparing the sites we
observed with a database of annotated sites (RedoxDB (51))
from composite studies across multiple organisms, we ob-
served that 40% of the Cys-SO2H/SO3H sites occur at pre-
viously identified reversibly modified Cys, and an additional
12% occur on proteins that have previously been identified as
redox modified at unknown sites (supplemental Table S4).
Extending this analysis to include our recent study of revers-
ibly modified Cys in the myocardium (7), we see that only 20%
of Cys-SO2H/SO3H modifications are located at sites that are
completely novel redox sites, i.e. not already known to be
occupied by a reversible Cys PTM (supplemental Table S4).
CONCLUSION
Cys-SO2H/SO3H sites are of particular interest as they
likely represent Cys residues with high reactivity or unique
microenvironments facilitating Cys-SOH stabilization and re-
action to higher oxidation states. We exploited the unique
characteristics of tryptic peptides containing Cys-SO2H/
SO3H to generate a novel method based on sequential: (1)
negative selection by electrostatic repulsion using SCX (which
separates them from the bulk of tryptic peptides); and then (2)
positive selection by hydrophilic interactions using HILIC
(which increases separation from other PTM-containing pep-
tides in the SCX FT and MeCN fractions). Increased fraction-
ation allows for the observation of a greater number of sites,
whereas also allowing for increases in starting material. This
improves the quality of MS data/spectral assignments and
potentially aids in the identification of low abundance sites.
Utilizing this strategy, we observed 181 Cys-SO2H/SO3H sites
in myocardial tissue extracts, which were treated with physi-
ological to pathological levels of H2O2, or were generated by
biologically relevant ex vivo Langendorff perfusion. The ma-
jority of Cys-SO2H/SO3H residues were located at sites pre-
viously identified as modified by reversible Cys modifications,
increasing the diversity of Cys PTM at these sites. Further-
more, we showed that even brief I/R injury induces significant
over-oxidation of myocardial proteins, which is consistent
with the oxidative damage assumed to occur during I/R. Ox-
idative protein damage of many targets may be a significant
contributor to contractile dysfunction and potentially a major
factor in pathways leading to myocyte apoptosis and necro-
sis. This technique is widely applicable to various sample
types and biological treatments, allowing for the discovery of
targets of Cys-SO2H/SO3H PTM induced by exposure to
ROS/RNS.
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